
Takeda has announced it is abandoning the development of a vaccine in Japan that was in Phase II clinical trials.TAK-361S, …

Rajeev Venkayya is the president of the global vaccine business unit at Takeda Pharmaceuticals. He has served as special assistant …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

